黄色软件免费观看_日本韓國三級國產歐美_在线综合亚洲欧美首页_手机看免费黄色毛片_黄色三级视频_国产 刺激 男女视觉盛宴_在线精品无码字幕无码αv_亚洲香蕉久久国产精品_温客行X周子舒车肉干_日韓歐美一區二區三區免費觀看

Entries by

SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR FYCOMPA? AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES, AS WELL AS NEW FORMULATION

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has filed a supplementary new drug application in Japan for its in-house discovered antiepileptic drug (AED) Fycompa??(perampanel) seeking approval for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.

2019/1/30 by

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FOURTH TIME

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been listed in the 2019 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai’s fourth inclusion on the list. Ranked 73rd, Eisai was the highest ranking Japanese company among the eight Japanese companies listed in the Global 100.

2019/1/22 by

2019 Lenvatinib Launching Ceremony Jointly Held by Eisai China and MSD China

On January 12, 2019, Eisai China Holdings Ltd. and MSD China Holding Co., Ltd. jointly held the 2019 Lenvatinib Launching Ceremony (Trademark: Lenvima?) in China, the domestic and foreign experts and scholars in the tumor field gathered together and conducted academic discussions on many issues, and they witnessed the launching of Assistance Project of Liver Cancer Patients.

2019/1/12 by

NEW DRUG APPLICATION FOR PERAMPANEL DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its in-house discovered and developed antiepileptic drug (AED) perampanel (generic name, product name: Fycompa?), for which ?a New Drug Application (NDA) was submitted for review as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older in China in October 2018, has been designated for Priority Review by the National Medical Products Administration (NMPA) due to perampanel’s significant clinical benefit compared to existing treatments.

2019/1/4 by

25 Students from China Medical University Win Eisai China Scholarships and Grants

The 2017-2018 Annual Awards Ceremony for Advanced Collectives and Outstanding Individuals of Undergraduates in China Medical University, held on Nov. 27, 2018, marks the kickoff of the “Eisai China Scholarships” and “Eisai China Grants” that Eisai China Inc. (ECI) provides to seven famous Chinese universities in 2018. Ms. Jun Zheng, ECI’s Senior Regional Manager of NTA Business Unit, Wenge He, Secretary of the Party Committee of the School of Pharmacy of China Medical University, and Xiaoyue Ji, Deputy Director of the Training Center of Rural Doctor of China, presented the awards to the representatives of the students.

2018/11/27 by

EISAI LAUNCHES LENVIMA? (LENVATINIB) IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA?(product name in China:?樂衛(wèi)瑪?, generic name: lenvatinib mesylate) in China.

2018/11/12 by

EISAI CHINA COMMENCES FULL-SCALE OPERATION OF NEW SUZHOU PLANT

November 7, 2018, Eisai China Inc. (ECI) held the inauguration ceremony for its new Suzhou plant located at No. 168 Xingpu Road within the Suzhou Industrial Park. Mr. Kazuyuki Katayama (Consulate-General of Japan in Shanghai), Mr. Yue Wang (Commissioner of Jiangsu Food and Drug Administration), Mr. Qingwen Wu (Standing Committee of Suzhou Municipality and Secretary General of the Party Committee of Suzhou Industrial Park Administrative Committee (SIPAC)), Ms. ?Yanyan Sun (Deputy Director of SIPAC), Mr. Jianmin Chen (Director-General of Suzhou Food and Drug Administration), Dr. Haruo Naito (CEO of Eisai Co., Ltd.), Mr. Yasushi Okada (Representative Corporate Officer of ECL, Industry Affairs and China Business), Ms. Yanhui Feng (Vice President of ECL, President of Eisai China), Mr. Norio Kaneko (Chairman of Eisai China) and people with close attention to the development of Eisai China attended the ceremony.

2018/11/7 by

Eisai China Inc. Held the “2018 ADS”

On October 27, 2018, the “2018 ADS” (ADS: Advance Dementia Science) was held by Eisai China Inc. in Beijing, China. The 2018 ADS is a communication platform that Eisai China established for doctors; the forum covers multi-aspects such as basic researches in the cognitive fields, new methods of diagnosis, clinical hotspots, research and development for new drugs, social and government policies, and etc., with well-known professors from China, Japan and South Korea discussing and interacting with over 300 participants on-site and over 400 participators online.?

2018/10/27 by

EISAI PRESENTS NEW DATA ON LEMBOREXANT FOR TREATMENT OF IRREGULAR SLEEP-WAKE RHYTHM DISORDER IN PATIENTS WITH ALZHEIMER’S DISEASE AT THE 11TH CLINICAL TRIALS IN ALZHEIMER’S DISEASE CONFERENCE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that Eisai presented new data from Study 202, a Phase II evaluation of lemborexant, an investigational sleep-wake regulation agent, for the treatment of Irregular Sleep-Wake Rhythm Disorder (ISWRD) in patients with mild to moderate Alzheimer’s disease. The data were presented at the 11th Clinical Trials in Alzheimer’s Disease (CTAD) Conference in Barcelona, Spain. Lemborexant is being developed for the treatment of multiple sleep-wake disorders, including insomnia disorder.

2018/10/26 by